 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- | iCP-NI / Cellivery
Journal: Intracellular delivery of nuclear localization sequence peptide mitigates COVID-19 by inhibiting nuclear transport of inflammation associated transcription factors. (Pubmed Central) - Jan 8, 2024
Similarly, in hamsters infected with SARS-CoV-2, iCP-NI effectively protected the lung from inflammatory damage by reducing TNF-?, IL-6, and IL-17 levels. These promising results highlight iCP-NI's potential as a therapeutic approach for COVID-19-related lung complications and other inflammatory lung diseases.
- |||| iCP-NI / Cellivery
Trial suspension: iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects (clinicaltrials.gov) - May 17, 2023
P1, N=64, Suspended, Sponsor: Cellivery Therapeutics, Inc.
These promising results highlight iCP-NI's potential as a therapeutic approach for COVID-19-related lung complications and other inflammatory lung diseases. Recruiting --> Suspended
- ||| iCP-NI / Cellivery
New P1 trial: iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects (clinicaltrials.gov) - Feb 23, 2023
P1, N=64, Recruiting, Sponsor: Cellivery Therapeutics, Inc.
- | CV-06 / Cellivery, Ildong
Journal: Intracellular delivery of Parkin rescues neurons from accumulation of damaged mitochondria and pathological α-synuclein. (Pubmed Central) - Apr 9, 2022
Last, iCP-Parkin prevented and reversed declines in tyrosine hydroxylase and dopamine expression concomitant with improved motor function induced by mitochondrial poisons or enforced α-synuclein expression. These results point to common, therapeutically tractable features in PD pathophysiology, and suggest that motor deficits in PD may be reversed, thus providing opportunities for therapeutic intervention after the onset of motor symptoms.
- iCP-NI / Cellivery
Intracellularly Delivered Nuclear Localization Sequence Attenuates The Severity Of COVID-19 By Inhibits Interaction Of Inflammatory Transcription Factors And Importins (Exhibit Hall; P331) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1764;
Likewise, the levels of inflammatory cytokines such as TNF-α and IL-17A in the lungs are significantly decreased and thereby, the lung structures are protected from inflammation-mediated damages. As a result, the iCP-NI could be developed as a novel medicine to cure various inflammatory diseases including COVID-19.
- iCP-NI / Cellivery
Intracellular Delivery Of Nuclear Localization Signal Relieves Inflammatory Pulmonal Disease Through Regulating Immune System By Patient-Friendly Inhalant Formulation (Exhibit Hall; P193) - Apr 8, 2022 - Abstract #IMMUNOLOGY2022IMMUNOLOGY_1651;
Also, iCP-NI inhibited the recruitment of neutrophils (99.8%) and macrophages (99.6%) in BALF, and thereby induced the restoration of damaged lung tissue. In conclusion, iCP-NI has a significant therapeutic effect on COPD through immune system control and potential as a patient-friendly anti-inflammatory drug.
- CV-06 / Cellivery, Ildong
A BRAIN-DELIVERABLE PARKIN PROTECTS NEURONS BY SUPPRESSING ACCUMULATION OF DAMAGED MITOCHONDRIA AND PATHOLOGICAL Α-SYNUCLEIN () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1720;
In conclusion, iCP-NI has a significant therapeutic effect on COPD through immune system control and potential as a patient-friendly anti-inflammatory drug. Based on these outcomes, iCP-Parkin has a great therapeutic potential as a PD-modifying agent with superior productivity.
- CV-06 / Cellivery, Ildong
BRAIN DELIVERY OF PARKIN WITH CELL-PERMEABILITY REDUCES AGGREGATED Β-AMYLOID AND RECOVERS COGNITIVE FUNCTION IN FIBRIL Β-AMYLOID-INDUCED ANIMALS () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1349;
Based on these outcomes, iCP-Parkin has a great therapeutic potential as a PD-modifying agent with superior productivity. In conclusion, the present outcome evidently supports the ability of iCP-Parkin to remove Aβ plaques and recover from cognitive dysfunction with mitochondria recovery, demonstrating its potential as a novel therapeutic agent against AD.